{"database":"ENA","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Fastqsanger.gz":["ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR310/076/SRR31096276/SRR31096276.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR310/074/SRR31096274/SRR31096274.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR310/070/SRR31096270/SRR31096270.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR310/081/SRR31096281/SRR31096281.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR310/079/SRR31096279/SRR31096279.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR310/068/SRR31096268/SRR31096268.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR310/072/SRR31096272/SRR31096272.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR310/069/SRR31096269/SRR31096269.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR310/077/SRR31096277/SRR31096277.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR310/075/SRR31096275/SRR31096275.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR310/080/SRR31096280/SRR31096280.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR310/078/SRR31096278/SRR31096278.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR310/073/SRR31096273/SRR31096273.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR310/082/SRR31096282/SRR31096282.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR310/071/SRR31096271/SRR31096271.fastq.gz"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["Translational Sciences Oncology Computational Biology, Bayer AG"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA1176846"],"scientific_name":["Homo sapiens"],"tag":["xref:PubMed:39769434"],"long_description":["LNCaP prostate cancer cells were stimulated with the synthetic androgen R1881. RNA-sequencing was performed to identify changes induced by darolutamide treatment on the transcriptome level. Overall design: Prostate androgen-sensitive cell lines LNCaP were grown for two days in starvation medium prior to treatment with synthetic androgen R1881 at a concentration of 1 nM or R1881 with darolutamide at a concentration of 2 µM. The cells were harvested 22 h post-induction for RNA isolation and sequencing."],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"RNA-sequencing of LNCaP prostate cancer cells with and without treatment of darolutamide","description":"RNA-sequencing of LNCaP prostate cancer cells with and without treatment of darolutamide","dates":{"last_updated":"2025-09-24","first_public":"2025-01-07"},"accession":"PRJNA1176846","cross_references":{"GEO":["GSE280187"],"taxon":["9606"],"PubMed":["39769434"]}}